Type
1.
Duthie MS, Hay, Rada, Convit, Ito, Oyafuso, et al. Specific IgG antibody responses may be used to monitor leprosy treatment efficacy and as recurrence prognostic markers. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2011;30(10):1257-65.
Type
1.
Lockwood DN. Leprosy (Hansen’s disease). 2003;:9 p.
Type
1.
Instituto Lauro de Souza Lima. [Relapse and drug resistance in leprosy]. Revista de saude publica [Internet]. 2011;45(3):631-3. Available from: http://www.scielo.br/pdf/rsp/v45n3/itss.pdf
Type
1.
Margoles, Rio, Franco-Paredes. Leprosy: a modern assessment of an ancient neglected disease. Bol Med Hosp Infant Mex [Internet]. 2011;68(2):120-6. Available from: http://www.nietoeditores.com.mx/download/bol_med_HIM/MARZO-ABRIL%202011/BOL%20Med%20Hosp%20espa%C3%B1ol/Bol%20Med%20Hosp%202.9%20LEPROSY.pdf
Type
1.
Quandelacy, Holtz, Franco-Paredes. Are leprosy reactions autoinflammatory diseases? Bol Med Hosp Infant Mex [Internet]. 2011;68(2):127-9. Available from: http://www.nietoeditores.com.mx/download/bol_med_HIM/MARZO-ABRIL%202011/BOL%20Med%20Hosp%20espa%C3%B1ol/Bol%20Med%20Hosp%202.10%20ARE.pdf
Type
1.
Lepra. Lepra News [Internet]. Colchester: Lepra ; 2020. Available from: https://mcusercontent.com/807c3628c6f141cdebd632a58/files/50a8290d-9d93-49d7-b3b7-46f12eebad46/ln_june_2020_FINAL_SMALL.pdf?utm_source=Master+list&utm_campaign=c0da6b7061-EMAIL_CAMPAIGN_2020_07_03_10_20&utm_medium=email&utm_term=0_5cfedbc134-c0da6b7061-43
Type
1.
Sachdeva S, Amin S, Khan Z, Sharma PK, Bansal S. Childhood leprosy: lest we forget. Tropical doctor. 2011;41(3):163-5.
Type
1.
Vilain P, Larrieu S, Camuset G, Pouderoux N, Gerber A, Borgherini G, et al. Leprosy, still present in La Réunion. Emerging infectious diseases [Internet]. 2012;18(1):188-9. Available from: http://wwwnc.cdc.gov/eid/article/18/1/pdfs/11-1176.pdf
Type
1.
Cardoso CC, Pereira AC, Sales Marques C, Moraes MO. Leprosy susceptibility: genetic variations regulate innate and adaptive immunity, and disease outcome. Future microbiology. 2011;6(5):533-49.
Type
1.
Massone, Talhari, Talhari, Brunasso, Campbell, Curcic, et al. Immunophenotype of skin lymphocytic infiltrate in patients co-infected with Mycobacterium leprae and human immunodeficiency virus: a scenario dependent on CD8+ and/or CD20+ cells. The British journal of dermatology. 2011;165(2):321-8.